Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jiangsu Hengrui Pharmaceuticals
Biotech
How Hengrui became a go-to source of China biopharma innovation
Fierce spoke to Lianshan Zhang, Ph.D., who's responsible for Hengrui's innovation ecosystem, to understand the pharma's history and its ambitions.
Leslie Zhen Liang
Oct 20, 2026 8:00am
Novo agrees $2.6B deal for Hengrui's preclinical GLP-1/GIP drug
Sep 29, 2026 3:50am
Braveheart charges to $382.5M IPO to fund Hengrui cardio drug
Aug 6, 2026 8:27am
Braveheart files for IPO to support Hengrui-licensed cardio asset
Jul 15, 2026 1:40pm
Kailera’s oral GLP-1 asset hits goals in Chinese phase 3 trials
Jul 7, 2026 8:44am
BMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed
May 12, 2026 1:56am
